RecruitingNot ApplicableNCT05844384

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial


Sponsor

59th Medical Wing

Enrollment

30 participants

Start Date

Mar 17, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether using a Nanodropper — a small device that fits on an eye drop bottle to reduce the size of each drop — works just as well as standard-sized eye drops for controlling eye pressure in people with primary open-angle glaucoma or ocular hypertension. Smaller drops reduce waste and may cause fewer side effects. **You may be eligible if...** - You are 18 or older - You have primary open-angle glaucoma or elevated eye pressure (ocular hypertension) - Your disease has been stable for at least the past year with no worsening of pressure, optic nerve, or vision - You are on no more than 2 eye pressure-lowering medications **You may NOT be eligible if...** - You have a different type of glaucoma (such as angle-closure or other secondary types) - Your glaucoma has been getting worse recently - You have had glaucoma surgery or laser treatment in the past 6 months - You require more than 2 glaucoma medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENanodropper

Nanodropper delivers 1/5 of eye drop volume compared to regular droppers

DEVICERegular dropper

Delivers full eye drop volume


Locations(1)

Wilford Hall Ambulatory Surgical Center

Lackland Air Force Base, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05844384


Related Trials